Quantification of 34 benzodiazepines in human plasma by LC-HRAM-MS for clinical research

Significance of the Topic

The quantification of benzodiazepines in human plasma is critical for clinical research, therapeutic drug monitoring, and forensic toxicology. These psychoactive compounds are widely prescribed for anxiety, insomnia, and seizure disorders but carry a high risk of misuse and abuse. A rapid, sensitive, and robust analytical method supports precise dose management, early detection of illicit use, and improved patient safety.

Study Objectives and Overview

The primary goal was to develop and validate a single liquid chromatography–high-resolution accurate mass spectrometry (LC-HRAM-MS) assay for simultaneous quantification of 34 benzodiazepines in human plasma. Key performance parameters included linearity, lower limit of quantitation (LLOQ), carryover, accuracy, and precision. The method was designed for high throughput in clinical research laboratories.

Methodology and Instrumentation

Sample Preparation

• Protein precipitation of 50 µL plasma with 100 µL acetonitrile containing internal standards
• Vortex mixing, centrifugation, and 1:1 dilution of supernatant with water

Chromatography

• System Thermo Scientific Vanquish Flex UHPLC
• Column Thermo Scientific Biphenyl 100 x 2.1 mm (2.6 µm) at 40 °C
• Mobile phases A water + 0.1% formic acid, B acetonitrile + 0.1% formic acid
• Gradient elution over 6.5 minutes, flow rate 0.5 mL/min, injection volume 2 µL

Mass Spectrometry

• Thermo Scientific Orbitrap Exploris 120 with heated electrospray ionization in positive mode
• Full-scan (m/z 70–450) at 60,000 resolution with data-dependent MS2 at 15,000 resolution
• Easy-IC internal calibration and HCD collision energy 30%
• Two fragment ions per analyte for confirmation and quantitation

Key Results and Discussion

Calibration and Linearity

• Analyte concentration ranges spanned 1.97 to 3,512 µg/L depending on compound
• Linear response with 1/x weighting and bias within ±16%

Lower Limit of Quantitation

• LLOQs from 0.502 to 75.3 µg/L across all 34 benzodiazepines

Carryover

• No significant carryover observed in blanks following highest calibrators

Accuracy and Precision

• Analytical bias for quality controls ranged –16% to +11%
• Intra-assay precision (CV) <7.6% for all analytes
• Inter-assay precision (CV) up to 14%

Benefits and Practical Applications

This method combines rapid sample preparation with a short chromatographic run, enabling high throughput analysis. The use of high-resolution mass spectrometry ensures confident analyte identification and quantitation in complex plasma matrices. Laboratories focused on clinical pharmacokinetics, therapeutic drug monitoring, and abuse screening can adopt this workflow for reliable results.

Future Trends and Applications

Advancements may include automation of sample preparation, further reduction of analysis time, and expansion to additional psychoactive compounds. Integration with laboratory information management systems (LIMS) and coupling to high-throughput screening platforms will streamline large-scale studies. Emerging HRAM-MS instruments with higher scan speeds and sensitivity will enable sub-µg/L quantitation and multiplexed assays.

Conclusion

A validated LC-HRAM-MS method on the Vanquish Flex UHPLC and Orbitrap Exploris 120 systems enables reliable quantification of 34 benzodiazepines in human plasma. The assay meets stringent criteria for linearity, sensitivity, accuracy, and precision, supporting diverse applications in clinical research and forensic testing.

References

Renoulin G Barcenas M De Nardi C Quantification of 34 benzodiazepines in human plasma by LC-HRAM-MS for clinical research Thermo Fisher Scientific Technical Note 66051 2021